GenOway: Accelerated Growth in China by genOway Shanghai

The French company genOway, specializing in preclinical solutions, has announced significant growth for its joint venture, genOway Shanghai, two years after its creation. This accelerated development reflects the rapid adoption of immuno-oncology models in China, exceeding initial forecasts. With anticipated annual revenue of nearly €2 million, genOway Shanghai is expected to reach profitability by the end of 2025, consolidating its strategic role within the group.

Already, more than 40 Chinese clients benefit from genOway Shanghai's services, including collaborations with major CROs in the country. The local production unit continues to expand its product range, facilitating a rapid response to the growing needs of the Chinese and Asian markets. With the goal of doubling its revenue by 2026, this expansion supports genOway's Route50+ strategic plan.